Inflammatory bowel disease: Potential new treatment target identified
The University of Oxford conducted a study on more than 200 patients’ with inflammatory bowel disease as well as two cohorts from phase 3 clinical trials of infliximab and golimumab. Conclusions drawn from this study suggest that a small protein involved in the inflammatory process could represent an effective target for drugs. As current methods of treatment have little to no effect on 40% of IBD patients, these proposed drugs could introduce a new way of treating the disorder. This could potentially have a substantial effect on the lifestyles of millions of patients worldwide.
Crohn’s and Colitis Australia would like to thank Medical News Today for permission to use this article.